Evropská unie - čeština - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pro dostupné údaje o různých kombinacích).

Evropská unie - čeština - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutid - diabetes mellitus, typ 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. pro výsledky studií s ohledem na kombinace, účinky na kontrolu glykémie a kardiovaskulárních příhod, a populace studoval, viz bod 4. 4, 4. 5 a 5.

Evropská unie - čeština - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin - diabetes mellitus, typ 2 - léky užívané při diabetu - trajenta je indikován k léčbě diabetes mellitus typu 2 ke zlepšení kontroly glykemie u dospělých:jako monotherapyin pacientů s nedostatečnou kompenzací dietou a cvičení sám a u kterých je metformin nevhodný z důvodu nesnášenlivosti či kontraindikován kvůli ledvin. jako kombinace therapyin kombinaci s metforminem v případech, kdy úprava stravy a cvičení při současném užívání metforminu samotného nezajistí dostatečnou kontrolu glykémie. v kombinaci se sulfonylureou a metforminem v případech, kdy dieta a cvičení dvojkombinační terapii těmito léčivými přípravky nezajistí dostatečnou kontrolu glykémie. v kombinaci s inzulinem, s metforminem nebo bez něj, kdy se tento režim sám, s dietou a cvičením neposkytují dostatečnou kontrolu glykémie.

Evropská unie - čeština - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - léky užívané při diabetu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pro dostupné údaje o různých kombinacích).

Evropská unie - čeština - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - pioglitazon, glimepirid - diabetes mellitus, typ 2 - léky užívané při diabetu - tandemact je indikován k léčbě pacientů s diabetes mellitus typu 2, nesnášenlivostí k metforminu nebo pro koho metformin je kontraindikován a kteří jsou již léčeni kombinace pioglitazonu a glimepirid.

Evropská unie - čeština - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiol monohydrát - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - léky užívané při diabetu - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. kromě jiných léčivých přípravků pro léčbu diabetu 2. typu. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Evropská unie - čeština - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiol monohydrát - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - léky užívané při diabetu - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. kromě jiných léčivých přípravků pro léčbu diabetu 2. typu. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Evropská unie - čeština - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - léky užívané při diabetu - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

belupo lijekovi i kozmetika, d.d., koprivnica array - 17128 vildagliptin - tableta - 50mg - vildagliptin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

heaton k.s., praha array - 41 monohydrÁt sitagliptin-hydrochloridu - potahovaná tableta - 100mg - sitagliptin